Enzalutamide
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Using the given Evidence Pack, I've noted this is a multi-candidate pack (TW-DB08899-multi) — of the 7 TxGNN-predicted indications, only one (rank 5, "benign reproductive system neoplasm") carries any real trial/literature evidence that represents a genuinely novel repurposing signal; rank 6 is flagged inside the pack itself as a re-detection of Enzalutamide's already-known indication (prostate cancer) rather than a repurposing candidate, and ranks 1–4/7 have zero supporting evidence. I've built the report around the one defensible candidate (rank 5) per the template, and added a portfolio table so the other 6 predictions aren't silently dropped.
Enzalutamide: From Prostate Cancer to Benign Reproductive System Neoplasm
One-Sentence Summary
Enzalutamide is a next-generation androgen receptor (AR) antagonist whose approved use — referenced throughout this evidence pack's own model rationale — is (metastatic/castration-resistant) prostate cancer. Of the seven new indications the TxGNN model surfaced for this drug, the only one supported by actual trial and literature evidence is Benign Reproductive System Neoplasm, with 1 clinical trial and 5 publications identified — all of them, however, drawn from malignant prostate cancer populations rather than the benign-neoplasm population itself, so the evidence is indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prostate Cancer (derived from the model's own repurposing rationale, which repeatedly cites this as "Enzalutamide 之核准適應症"; formal Taiwan/BfArM licensed indication text is not available — see Data Gap DG001/DG002) |
| Predicted New Indication | Benign Reproductive System Neoplasm |
| TxGNN Prediction Score | 99.53% (global model rank #5656) |
| Evidence Level | L4 |
| Germany Market Status | ✗ Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is marked as a data gap (original_moa: [Data Gap]), but the model's own rationale text consistently describes Enzalutamide as a next-generation AR antagonist that blocks AR nuclear translocation, DNA binding, and co-activator recruitment — the core mechanism by which it suppresses androgen-driven prostate cancer growth.
Prostate cancer (the drug's approved use) and "benign reproductive system neoplasm" both fall under AR-influenced growth pathways within the prostate/reproductive organ system. Several of the supporting publications (e.g., PMID 26926093, PMID 31266892) describe AR signaling and androgen biotransformation as active in both benign and malignant prostate tissue, which is the theoretical basis for extrapolating AR blockade to non-malignant proliferative lesions.
The key limitation is that none of the identified trials or literature actually studied a benign-neoplasm population — all clinical and mechanistic data come from malignant, metastatic, or castration-resistant prostate cancer cohorts. The link to "benign reproductive system neoplasm" is therefore a plausible mechanistic extrapolation, not a directly demonstrated effect, which is why the evidence level is capped at L4 (preclinical/mechanistic) rather than higher.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05701007 | N/A (observational) | Completed | 1,083 | Real-world epidemiology and treatment-pattern study of metastatic (malignant) prostate cancer patients in Finland; provides population-level background only — study population and design do not match a benign-neoplasm indication (relevance grade C). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26926093 | 2016 | Review | Pharmacological Research | Reviews androgen biotransformation and the AR/UGT regulatory network active in both benign and malignant prostate cells, supporting a shared hormonal growth-control pathway. |
| 35227084 | 2022 | Translational/Biomarker Cohort | The Journal of Urology | Shows PSMA as a biomarker for residual disease after neoadjuvant androgen deprivation, demonstrating androgen blockade's measurable effect on prostate tissue histology. |
| 33771918 | 2021 | Preclinical/Mechanistic | PNAS | ERβ activation inhibits nuclear EGFR translocation in the prostate, pointing to estrogen-receptor-linked regulation of prostate epithelial growth relevant to non-malignant proliferation. |
| 31266892 | 2019 | Preclinical/Mechanistic | PNAS | PARP-2 inhibition disrupts FOXA1-driven AR signaling and suppresses prostate growth — mechanistic support for AR-pathway targeting of prostate tissue growth in general. |
| 30864728 | 2019 | Preclinical/Mechanistic | Oncology Reports | PLCε knockdown sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing AR signaling — a resistance-reversal mechanism, not benign-tissue data. |
Other Predicted Indications (Portfolio Overview)
Because this evidence pack contains 7 model-predicted indications for Enzalutamide, they are summarized here for completeness rather than silently discarded:
| Rank | Disease | TxGNN Score | Evidence Level | Decision | Note |
|---|---|---|---|---|---|
| 1 | Prostate cancer/brain cancer susceptibility | 99.71% | L5 | Hold | Compound ontology term; no CNS mechanistic link, no evidence. Enzalutamide has limited blood-brain-barrier penetration and reported CNS AEs (seizure) — a safety signal, not an efficacy rationale. |
| 2 | Prostate leiomyoma | 99.57% | L5 | Hold | Rare benign stromal tumor; growth driver unclear and not established as AR-dependent. No evidence. |
| 3 | Brenner tumor | 99.55% | L5 | Hold | Predominantly an ovarian tumor; organ-system link to Enzalutamide's approved use is weak. No evidence. |
| 4 | Fibroma of prostate | 99.53% | L5 | Hold | Rare benign stromal tumor; no literature establishing AR-pathway involvement. No evidence. |
| 5 | Benign reproductive system neoplasm | 99.53% | L4 | Hold (Research Question) | Headline candidate above — only entry with real, if indirect, supporting evidence. |
| 6 | Male reproductive organ cancer | 99.51% | L2 | Excluded | This is essentially Enzalutamide's already-approved indication (prostate cancer) — 50 trials and 20 publications confirm this, but the pack itself flags it as a positive-control signal confirming model accuracy, not a novel repurposing candidate, and recommends excluding it from the candidate list. |
| 7 | Benign prostate phyllodes tumor | 99.48% | L5 | Hold | Extremely rare biphasic tumor, typically breast-origin; essentially no prostate-specific literature. No evidence. |
Cytotoxicity
(Included because the drug's approved indication is oncologic — prostate cancer — even though Enzalutamide is not a conventional chemotherapeutic.)
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — next-generation androgen receptor (AR) signaling inhibitor; not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions (no toxicity data provided in this evidence pack) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions (no data provided) |
| Monitoring Items | Please refer to the package insert warnings and precautions. Note: the pack's own rationale (rank 1) flags a reported CNS safety signal (seizure) associated with Enzalutamide, suggesting neurological monitoring is relevant where applicable |
| Handling Protection | Please refer to the package insert warnings and precautions (no cytotoxic-handling data provided; oral targeted agent, not classic IV cytotoxic chemotherapy) |
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and drug-interaction data are all marked as data gaps in this pack. Note that DG001 — TFDA/BfArM package-insert warnings and contraindications — is flagged as a Blocking severity gap: the pack itself states this data must be resolved before the candidate can enter the S1 safety pre-screen.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The only novel, evidence-backed candidate in this pack (Benign Reproductive System Neoplasm, rank 5) is supported solely by indirect, mechanistic/preclinical evidence drawn from malignant prostate cancer populations (L4) — no trial or publication studies the benign-neoplasm population directly.
- The drug is currently unmarketed in the relevant regulatory jurisdiction (0 licenses), and a Blocking-severity data gap (TFDA/BfArM package-insert warnings and contraindications, DG001) prevents even a basic safety pre-screen.
- The remaining five low-scoring candidates (ranks 1–4, 7) have zero supporting trials or literature; rank 6 duplicates the drug's already-approved indication and should be excluded from the candidate list rather than pursued as "new."
To proceed, the following is needed:
- TFDA/BfArM package insert (warnings, contraindications) — resolves DG001 (Blocking)
- Confirmed mechanism-of-action documentation from DrugBank — resolves DG002
- A direct preclinical or translational study evaluating AR blockade in benign (non-malignant) reproductive-tract neoplasm tissue, to move rank 5 beyond mechanistic extrapolation
- Clarification of German/Taiwan regulatory and licensing status, given the drug is currently unmarketed with 0 authorizations on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.